Studies on the analysis of antigen recognition mechanisms of Lyt- <1^+> <2^-> T cells mediating in vivo cell-mediated immunity and the regulation of induction of these cells.

Lyt-<1^><2^->T细胞介导体内细胞介导免疫的抗原识别机制分析及其诱导调节的研究。

• 批准号: 60480176
• 负责人: FUJIWARA Hiromi
• 金额: $ 4.35万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1985
• 资助国家: 日本
• 起止时间: 1985 至 1986
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-60480176/
• 关键词: Lyt- <1^+> <2^-> T cells; helper T cells; delayed-type hypersensitivity; antigen-presenting cells; major histocompatibility complex antigens; 免疫寛容

This purpose aimed to (1) establish various assay systems capable assessing activities of Lyt- <1^+> <2^-> T cells responsible for various immune responses in vivo and (2) to analyze the mechanisms by which these T cells recognize antigens and (3) to investigate the manipulation of in vivo immune phenomena such as tumor or allograft rejections and autoimmune disease by regulating the induction of the Lyt- <1^+> <2^-> T cellsThe results demonstrated that (1) assay systems were established for assessing various Lyt- <1^+> <2^-> T cell activities. These included helper T cell activities assisting CTL or antibody responses to cell-bound antigens (cell surface antigens), and delayed-type hypersensitivity responses; (2) lyt- <1^+> <2^-> T cells can recognize cell surface antigens when these antigens are shed off from cell surfaces, processed by antigen-presenting cells (APC) and presented by APC in association with class II MHC antigens on APC; and (3) portal venous administration of allogeneic cells results in alloantigen-specific tolerance of delayed-type hypersensitivity responses and this approach is applicable to the regulation of transplantation immunity particularly when combined with an appropriate drug such as cyclophos-phamide.

本发明的目的在于（1）建立能够评估体内各种免疫应答的Lyt- <1^+> <2^-> T细胞的活性的各种测定系统，（2）分析这些T细胞识别抗原的机制，（3）研究通过调节Lyt-<1 ^+><2^-> T细胞的诱导来操纵体内免疫现象，例如肿瘤或同种异体移植排斥和自身免疫性疾病。<1^+> <2^-> T细胞结果表明：（1）建立了测定各种Lyt- <1^+> <2^-> T细胞活性的测定系统。这些包括辅助性T细胞活动，协助CTL或抗体对细胞结合抗原的反应（2）lyt- <1^+> <2^-> T细胞能够识别细胞表面抗原，当这些抗原从细胞表面脱落，被抗原呈递细胞（APC）加工并被APC与APC上的II类MHC抗原联合呈递时;和（3）同种异体细胞的门静脉给药导致延迟型超敏反应的同种异体抗原特异性耐受，并且该方法适用于移植免疫的调节，特别是当与适当的药物如环磷酰胺组合时。

项目成果

Hiromi Fujiwara: "Helper T cells against tumor-associated antigens (TAA): Preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses." J. Immunol.136. 2715-2719 (1986)

Hiromi Fujiwara：“针对肿瘤相关抗原 (TAA) 的辅助 T 细胞：优先诱导参与抗 TAA 细胞毒性 T 淋巴细胞和抗体反应的辅助 T 细胞活性。”

Jia-hua Qian: J.Immunol.134. 3556-3661 (1985)

钱家华：J.Immunol.134。

Hiromi Fujiwara: J.Immunol.136. 2763-2768 (1986)

藤原宏美：J.Immunol.136。

Jia-hua Qian: Transplantation. (1987)

钱家华：移植。

Hiromi Fujiwara: "Studies on the induction of tolerance to alloantigens. II.The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed type-hypersensitivity by portal venous inoculation with allogeneic cells." J. Immunol

Hiromi Fujiwara：“诱导同种异体抗原耐受性的研究。II.通过门静脉接种同种异体细胞，产生能够转移迟发型超敏反应的同种异体抗原特异性耐受性的血清因子。”